Shenzhen Hepalink to acquire Scientific Protein Laboratories for US$337.5m

Published: 7-Jan-2014
Ingredients Finance

Combined company will be a global leader in Heparin Sodium API supply


Chinese firm Shenzhen Hepalink Pharmaceutical plans to buy US-based Scientific Protein Laboratories (SPL), a manufacturer and supplier of active pharmaceutical ingredients (APIs), for US$337.5m.

With the deal, the firm aims to expand its presence as a leading supplier of heparin worldwide, while providing greater product development and growth opportunities in new markets for its full line of APIs, including pancreatic enzyme and heparin products.

Li Li, Chairman and Chief Executive of Hepalink, said the deal would enable the firm to 'further enhance the stability and safety of the supply of the heparin product raw materials'.

Robert Mills, Chief Executive of SPL, added that the deal would 'expand our ability to develop and grow both our domestic and international businesses and to continue to conduct cutting-edge research on new products. We do not anticipate any changes in how we currently do business.'

The transaction is expected to be completed during the first half of 2014. After completion, SPL’s management will remain in place, as will its 204 employees in the US. SPL’s main facility is in Waunakee, Wisconsin.

  • Companies:
  • Scientific Protein Laboratories LLC
  • Shenzhen Hepalink Pharmaceutical Co. Ltd
See more

You may also like

Finance

Hepalink USA to acquire Cytovance Biologics

Read more
Hepalink investment will give Cytovance the opportunity to develop both its domestic and international businesses and to secure its plans to expand its Oklahoma City facilities

Trending Articles

  1. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  2. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach
  3. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  4. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  5. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Finance

Hepalink USA to acquire Cytovance Biologics

Hepalink investment will give Cytovance the opportunity to develop both its domestic and international businesses and to secure its plans to expand its Oklahoma City facilities
Ingredients

FrieslandCampina Ingredients debuts consumer-driven concepts at Vitafoods Europe

The company will exhibit its omega-3 ingredient, as well as its active gut health solution
Drug Delivery

Adult vaccination programmes deliver significant socio-economic benefits, study finds

The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium
Ingredients

Therapeutic: lutikizumab for hidradenitis suppurativa

Hidradenitis suppurativa (HS) — also known as acne inversa — is a chronic, recurrent and progressive inflammatory disease that leads to irreversible skin damage and disability
Ingredients

Olon: celebrating 10 years of daptomycin and doubled production capacity

Olon's Daptomycin celebrates its 10th anniversary, and in the very year that marks the first decade of production of this first in a new class of antibiotics that represented a breakthrough in the treatment of skin infections, the leading API supplier group announces the doubling of its production to meet and exceed global demand for the active ingredient
Subscribe now